Janine Baumgart1, Florian Jungmann2, Fabian Bartsch1, Michael Kloth3, Jens Mittler1, Stefan Heinrich4, Hauke Lang1. 1. Department of General, Visceral and Transplantation Surgery, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany. 2. Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany. 3. Department of Pathology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany. 4. Department of General, Visceral and Transplantation Surgery, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany. stefan.heinrich@unimedizin-mainz.de.
Abstract
BACKGROUND AND AIM: Two-stage hepatectomy (TSH) with or without portal vein ligation (PVL) or portal vein embolization (PVE) and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) are surgical strategies in the treatment of advanced colorectal liver metastases (CRLM). The role of each strategy is yet ill defined. The aim of this analysis is to share our center experience with conventional TSH with or without PVL/PVE and ALPPS in patients with advanced bilateral CRLM. PATIENTS AND METHODS: Data were extracted from a prospectively collected institutional database. Complication rates according to the Dindo-Clavien classification, overall and recurrence-free survival data were analyzed. RESULTS: Between 2008 and 2017, 790 liver resections were performed in 611 patients with CRLM. Out of 320 patients with bilateral disease, TSH (as right or extended right hepatectomy) with or without PVL/PVE was performed in 50 patients and ALPPS in 8. Stage 2 was completed in 36 (72%) out of 50 TSH/PVL/PVE and in all ALPPS patients (100%). Median follow-up was 15.8 months (0.9 to 111.9 months). On an intention-to-treat basis, the median overall survival was 26.7 (21.8-35.1 range) months after TSH/PVL/PVE and 36.2 months (11.3-61.2 range) after ALPPS (p = 0.809). In the TSH/PVL/PVE cohort, the median overall survival was 29.9 (19.0-40.3) months in patients who completed stage 2 compared to 13.8 months in patients who did not (p < 0.001). Disease recurred in 60% in the TSH/PVL/PVE cohort and in 87.5% in the ALPPS cohort (p = 0.777). The median recurrence-free survival was 5.9 (1.7-18.6) months after TSH/PVL/PVE and 3 (1.6-14.8) months after ALPPS (p = 0.680). CONCLUSION: The treatment of advanced bilateral CRLM remains a surgical and oncological challenge. A tailored approach to bilateral CRLM uses TSH/PVL/PVE as first and ALPPS as second rescue treatment in order to achieve resectability in patients with extensive tumor burden not amenable to one-stage resection. ALPPS should be reserved for patients with no other surgical options.
BACKGROUND AND AIM: Two-stage hepatectomy (TSH) with or without portal vein ligation (PVL) or portal vein embolization (PVE) and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) are surgical strategies in the treatment of advanced colorectal liver metastases (CRLM). The role of each strategy is yet ill defined. The aim of this analysis is to share our center experience with conventional TSH with or without PVL/PVE and ALPPS in patients with advanced bilateral CRLM. PATIENTS AND METHODS: Data were extracted from a prospectively collected institutional database. Complication rates according to the Dindo-Clavien classification, overall and recurrence-free survival data were analyzed. RESULTS: Between 2008 and 2017, 790 liver resections were performed in 611 patients with CRLM. Out of 320 patients with bilateral disease, TSH (as right or extended right hepatectomy) with or without PVL/PVE was performed in 50 patients and ALPPS in 8. Stage 2 was completed in 36 (72%) out of 50 TSH/PVL/PVE and in all ALPPS patients (100%). Median follow-up was 15.8 months (0.9 to 111.9 months). On an intention-to-treat basis, the median overall survival was 26.7 (21.8-35.1 range) months after TSH/PVL/PVE and 36.2 months (11.3-61.2 range) after ALPPS (p = 0.809). In the TSH/PVL/PVE cohort, the median overall survival was 29.9 (19.0-40.3) months in patients who completed stage 2 compared to 13.8 months in patients who did not (p < 0.001). Disease recurred in 60% in the TSH/PVL/PVE cohort and in 87.5% in the ALPPS cohort (p = 0.777). The median recurrence-free survival was 5.9 (1.7-18.6) months after TSH/PVL/PVE and 3 (1.6-14.8) months after ALPPS (p = 0.680). CONCLUSION: The treatment of advanced bilateral CRLM remains a surgical and oncological challenge. A tailored approach to bilateral CRLM uses TSH/PVL/PVE as first and ALPPS as second rescue treatment in order to achieve resectability in patients with extensive tumor burden not amenable to one-stage resection. ALPPS should be reserved for patients with no other surgical options.
Entities:
Keywords:
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS); Liver surgery; Surgical management of bilateral colorectal liver metastases; Two-stage hepatectomy
Authors: M Narita; E Oussoultzoglou; D Jaeck; P Fuchschuber; E Rosso; P Pessaux; E Marzano; P Bachellier Journal: Br J Surg Date: 2011-06-28 Impact factor: 6.939
Authors: Dimitrios Moris; Sean Ronnekleiv-Kelly; Ioannis D Kostakis; Diamantis I Tsilimigras; Eliza W Beal; Alexandros Papalampros; Dimitrios Dimitroulis; Evangelos Felekouras; Timothy M Pawlik Journal: World J Surg Date: 2018-03 Impact factor: 3.352
Authors: John T Mullen; Dario Ribero; Srinevas K Reddy; Matteo Donadon; Daria Zorzi; Shiva Gautam; Eddie K Abdalla; Steven A Curley; Lorenzo Capussotti; Bryan M Clary; Jean-Nicolas Vauthey Journal: J Am Coll Surg Date: 2007-02-15 Impact factor: 6.113
Authors: Eddie K Abdalla; Dario Ribero; Timothy M Pawlik; Daria Zorzi; Steven A Curley; Andrea Muratore; Axel Andres; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2007-01 Impact factor: 3.452
Authors: Luca Viganò; Lorenzo Capussotti; Réal Lapointe; Eduardo Barroso; Catherine Hubert; Felice Giuliante; Jan N M Ijzermans; Darius F Mirza; Dominique Elias; René Adam Journal: Ann Surg Oncol Date: 2013-12-18 Impact factor: 5.344
Authors: L Viganò; G Torzilli; M Cimino; K Imai; E Vibert; M Donadon; D Castaing; R Adam Journal: Eur J Surg Oncol Date: 2016-04-26 Impact factor: 4.424
Authors: Kenneth Cardona; Dino Donataccio; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Andrea Cercek; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2013-11-18 Impact factor: 5.344
Authors: Jan Bednarsch; Zoltan Czigany; Samara Sharmeen; Gregory van der Kroft; Pavel Strnad; Tom Florian Ulmer; Peter Isfort; Philipp Bruners; Georg Lurje; Ulf Peter Neumann Journal: World J Surg Oncol Date: 2020-06-24 Impact factor: 2.754